Head and Neck Pathology

, Volume 12, Issue 1, pp 22–30 | Cite as

Sinonasal Neuroendocrine Neoplasms: Current Challenges and Advances in Diagnosis and Treatment, with a Focus on Olfactory Neuroblastoma

  • Diana BellEmail author
Proceedings of the North American Society of Head and Neck Pathology Companion Meeting, March 18, 2018, Vancouver, British Columbia, Canada


Sinonasal tumors with neuroendocrine differentiation form a group of rare heterogeneous neoplasms of neuroectodermal and epithelial origin, consisting of olfactory neuroblastomas and neuroendocrine carcinomas. Because the natural history and biological behavior of this group of tumors vary, the morphological diagnosis coupled with grading/staging is important for prognostication, and the approach to treatment and rehabilitation is multidisciplinary. The identification of molecular abnormalities underlying these tumors is critical to the development of specific targeted therapies and the design of clinical trials.


Sinonasal neuroendocrine tumors Sinonasal small cell carcinoma Sinonasal large cell carcinoma Olfactory neuroblastoma 


Compliance with Ethical Standards

Conflict of interest

The author declares that she has no competing interests.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.


  1. 1.
    Bell D, Hanna EY, Weber RS, et al. Neuroendocrine neoplasms of the sinonasal region. Head Neck. 2016;38(Suppl 1):E2259–66.CrossRefPubMedGoogle Scholar
  2. 2.
    La Rosa S, Sessa F, Uccella S. Mixed neuroendocrine-nonneuroendocrine neoplasms (MiNENs): unifying the concept of a heterogeneous group of neoplasms. Endocr Pathol. 2016;27(4):284–311.CrossRefPubMedGoogle Scholar
  3. 3.
    Uccella S, Ottini G, Facco C, et al. Neuroendocrine neoplasms of the head and neck and olfactory neuroblastoma. Diagnosis classification. Pathologica. 2017;109(1):14–30.PubMedGoogle Scholar
  4. 4.
    Hendifar AE, Marchevsky AM, Tuli R. Neuroendocrine tumors of the lung: current challenges and advances in the diagnosis and management of well-differentiated disease. J Thorac Oncol. 2017;12(3):425–36.CrossRefPubMedGoogle Scholar
  5. 5.
    La Rosa S, Furlan D, Franzi F, et al. Mixed exocrine-neuroendocrine carcinoma of the nasal cavity: clinico-pathologic and molecular study of a case and review of the literature. Head Neck Pathol. 2013;7(1):76–84.CrossRefPubMedGoogle Scholar
  6. 6.
    Su SY, Bell D, Hanna EY. Esthesioneuroblastoma, neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma: differentiation in diagnosis and treatment. Int Arch Otorhinolaryngol. 2014;18(Suppl 2):S149–56.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Thompson LDR, Bell D, Bishop JA. Neuroendocrine carcinomas. In: El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ, editors. WHO classification of tumors of the head and neck. 4th ed. Tumors of the nasal cavity, paranasal sinuses and skull base. Lyon: IAC Press; 2017. pp. 21–3.Google Scholar
  8. 8.
    Mitchell EH, Diaz A, Yilmaz T, et al. Multimodality treatment for sinonasal neuroendocrine carcinoma. Head Neck. 2012;34(10):1372–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Mills SE. Neuroectodermal neoplasms of the head and neck with emphasis on neuroendocrine carcinomas. Mod Pathol. 2002;15(3):264–78.CrossRefPubMedGoogle Scholar
  10. 10.
    Rosenthal DI, Barker JL Jr, El-Naggar AK, et al. Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. Cancer. 2004;101(11):2567–73.CrossRefPubMedGoogle Scholar
  11. 11.
    Bell D, Hanna EY. Sinonasal undifferentiated carcinoma: morphological heterogeneity, diagnosis, management and biological markers. Expert Rev Anticancer Ther. 2013;13(3):285–96.CrossRefPubMedGoogle Scholar
  12. 12.
    Renner G. Small cell carcinoma of the head and neck: a review. Semin Oncol. 2007;34(1):3–14.CrossRefPubMedGoogle Scholar
  13. 13.
    Babin E, Rouleau V, Vedrine PO, et al. Small cell neuroendocrine carcinoma of the nasal cavity and paranasal sinuses. J Laryngol Otol. 2006;120(4):289–97.CrossRefPubMedGoogle Scholar
  14. 14.
    Fitzek MM, Thornton AF, Varvares M, et al. Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. Cancer. 2002;94(10):2623–34.CrossRefPubMedGoogle Scholar
  15. 15.
    van der Laan TP, Iepsma R, Witjes MJ, van der Laan BF, Plaat BE, Halmos GB. Meta-analysis of 701 published cases of sinonasal neuroendocrine carcinoma: the importance of differentiation grade in determining treatment strategy. Oral Oncol. 2016;63:1–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Berger L, Luc R, Richard D. “L’esthesioneuroepitheliome Olfactif.” Bulletin de l’Association Fran?aise pour l’étude du Cancer.vol 13. 1924. pp. 410–21.Google Scholar
  17. 17.
    Bell D, Franchi A, Gillison M, Thompson LDR, Wenig BM. Olfactory neuroblastoma. In: El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ, editors. WHO classification of tumors of the head and neck. 4th ed. Tumors of the nasal cavity, paranasal sinuses and skull base. Lyon: IAC Press; 2017. pp. 57–9.Google Scholar
  18. 18.
    Holmes M, Su SY, Bell D. Ectopic primary olfactory neuroblastoma of the maxillary sinus. Ann Diagn Pathol. 2016;22:45–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Ow TJ, Bell D, Kupferman ME, Demonte F, Hanna EY. Esthesioneuroblastoma. Neurosurg Clin N Am. 2013;24(1):51–65.CrossRefPubMedGoogle Scholar
  20. 20.
    Faragalla H, Weinreb I. Olfactory neuroblastoma: a review and update. Adv Anat Pathol. 2009;16(5):322–31.CrossRefPubMedGoogle Scholar
  21. 21.
    Holbrook EH, Wu E, Curry WT, Lin DT, Schwob JE. Immunohistochemical characterization of human olfactory tissue. Laryngoscope. 2011;121(8):1687–701.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Lavoie J, Gasso Astorga P, Segal-Gavish H, et al. The olfactory neural epithelium as a tool in neuroscience. Trends Mol Med. 2017;23(2):100–3.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Bell D, Saade R, Roberts D, et al. Prognostic utility of Hyams histological grading and Kadish-Morita staging systems for esthesioneuroblastoma outcomes. Head Neck Pathol. 2015;9(1):51–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Jethanamest D, Morris LG, Sikora AG, Kutler DI. Esthesioneuroblastoma - A population-based analysis of survival and prognostic factors. Arch Otolaryngol Head Neck Surg. 2007;133(3):276–80.CrossRefPubMedGoogle Scholar
  25. 25.
    Platek ME, Merzianu M, Mashtare TL, et al. Improved survival following surgery and radiation therapy for olfactory neuroblastoma: analysis of the SEER database. Radiat Oncol. 2011;6:41.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer. 1976;37(3):1571–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, Quast LM. Esthesioneuroblastoma: prognosis and management. Neurosurgery. 1993;32(5):706–14 (discussion 714–705).CrossRefPubMedGoogle Scholar
  28. 28.
    Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970–1990. Laryngoscope. 1992;102(8):843–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Hyams VJ. Olfactory neuroblastoma (case 6). In: Batsakis JG, Hyams VJ, Morales AR, editors. Special tumors of the head and neck. Chicago: ASCP Press; 1982. pp. 24–9.Google Scholar
  31. 31.
    Saade RE, Hanna EY, Bell D. Prognosis and biology in esthesioneuroblastoma: the emerging role of Hyams grading system. Curr Oncol Rep. 2015;17(1):423.CrossRefPubMedGoogle Scholar
  32. 32.
    Kaur G, Kane AJ, Sughrue ME, et al. The prognostic implications of Hyam’s subtype for patients with Kadish stage C esthesioneuroblastoma. J Clin Neurosci. 2013;20(2):281–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Malouf GG, Casiraghi O, Deutsch E, Guigay J, Temam S, Bourhis J. Low- and high-grade esthesioneuroblastomas display a distinct natural history and outcome. Eur J Cancer. 2013;49(6):1324–34.CrossRefPubMedGoogle Scholar
  34. 34.
    Van Gompel JJ, Giannini C, Olsen KD, et al. Long-term outcome of esthesioneuroblastoma: Hyams grade predicts patient survival. J Neurol Surg Part B. 2012;73(5):331–6.CrossRefGoogle Scholar
  35. 35.
    Mandarano M, Colella R, Giansanti M, Sidoni A. Aberrant pattern of cytokeratin expression in olfactory neuroblastoma: a potential diagnostic pitfall. Head Neck Pathol. 2017;11(2):262–3.CrossRefPubMedGoogle Scholar
  36. 36.
    Singh L, Ranjan R, Madan R, Arava SK, Deepak RK, Singh MK. Microvessel density and Ki-67 labeling index in esthesioneuroblastoma: is there a prognostic role? Ann Diagn Pathol. 2015;19(6):391–6.CrossRefPubMedGoogle Scholar
  37. 37.
    Turri-Zanoni M, Maragliano R, Battaglia P, et al. The clinicopathological spectrum of olfactory neuroblastoma and sinonasal neuroendocrine neoplasms: refinements in diagnostic criteria and impact of multimodal treatments on survival. Oral Oncol. 2017;74:21–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Thompson LD, Seethala RR, Muller S. Ectopic sphenoid sinus pituitary adenoma (ESSPA) with normal anterior pituitary gland: a clinicopathologic and immunophenotypic study of 32 cases with a comprehensive review of the english literature. Head Neck Pathol. 2012;6(1):75–100.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Holland H, Koschny R, Krupp W, et al. Comprehensive cytogenetic characterization of an esthesioneuroblastoma. Cancer Genet Cytogenet. 2007;173(2):89–96.CrossRefPubMedGoogle Scholar
  40. 40.
    Bockmuhl U, You X, Pacyna-Gengelbach M, Arps H, Draf W, Petersen I. CGH pattern of esthesioneuroblastoma and their metastases. Brain Pathol. 2004;14(2):158–63.CrossRefPubMedGoogle Scholar
  41. 41.
    Riazimand SH, Brieger J, Jacob R, Welkoborsky HJ, Mann WJ. Analysis of cytogenetic aberrations in esthesioneuroblastomas by comparative genomic hybridization. Cancer Genet Cytogenet. 2002;136(1):53–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Guled M, Myllykangas S, Frierson HF Jr, Mills SE, Knuutila S, Stelow EB. Array comparative genomic hybridization analysis of olfactory neuroblastoma. Mod Pathol. 2008;21(6):770–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Valli R, De Bernardi F, Frattini A, et al. Comparative genomic hybridization on microarray (a-CGH) in olfactory neuroblastoma: analysis of ten cases and review of the literature. Genes Chromosom Cancer. 2015;54(12):771–5.CrossRefPubMedGoogle Scholar
  44. 44.
    Mao L, Xia YP, Zhou YN, et al. Activation of sonic hedgehog signaling pathway in olfactory neuroblastoma. Oncology. 2009;77(3–4):231–43.CrossRefPubMedGoogle Scholar
  45. 45.
    Gonzalez-Kristeller DC, Gutiyama LM, Campos AH, Soares FA, Brentani H, Malnic B. Odorant receptor genes are expressed in olfactory neuroblastoma. Genet Mol Res. 2013;12(3):3479–87.CrossRefPubMedGoogle Scholar
  46. 46.
    Ball DW, Azzoli CG, Baylin SB, et al. Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumors. Proc Natl Acad Sci USA. 1993;90(12):5648–52.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Augustyn A, Borromeo M, Wang T, et al. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc Natl Acad Sci USA. 2014;111(41):14788–93.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Persson P, Jogi A, Grynfeld A, Pahlman S, Axelson H. HASH-1 and E2-2 are expressed in human neuroblastoma cells and form a functional complex. Biochem Biophys Res Commun. 2000;274(1):22–31.CrossRefPubMedGoogle Scholar
  49. 49.
    Mhawech P, Berczy M, Assaly M, et al. Human achaete-scute homologue (hASH1) mRNA level as a diagnostic marker to distinguish esthesioneuroblastoma from poorly differentiated tumors arising in the sinonasal tract. Am J Clin Pathol. 2004;122(1):100–5.CrossRefPubMedGoogle Scholar
  50. 50.
    Cordes B, Williams MD, Tirado Y, et al. Molecular and phenotypic analysis of poorly differentiated sinonasal neoplasms: an integrated approach for early diagnosis and classification. Hum Pathol. 2009;40(3):283–92.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Taggart MW, Hanna EY, Gidley P, Weber RS, Bell D. Achaete-scute homolog 1 expression closely correlates with endocrine phenotype and degree of differentiation in sinonasal neuroendocrine tumors. Ann Diagn Pathol. 2015;19(3):154–6.CrossRefPubMedGoogle Scholar
  52. 52.
    Gay LM, Kim S, Fedorchak K, et al. Comprehensive genomic profiling of esthesioneuroblastoma reveals additional treatment options. Oncologist. 2017;22(7):834–42.CrossRefPubMedGoogle Scholar
  53. 53.
    Czapiewski P, Kunc M, Haybaeck J. Genetic and molecular alterations in olfactory neuroblastoma: implications for pathogenesis, prognosis and treatment. Oncotarget. 2016;7(32):52584–96.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Lazo de la Vega L, McHugh JB, Cani AK, et al. Comprehensive molecular profiling of olfactory neuroblastoma identifies potentially targetable FGFR3 amplifications. Mol Cancer Res. 2017;15(11):1551–7.CrossRefGoogle Scholar
  55. 55.
    Ow TJ, Hanna EY, Roberts DB, et al. Optimization of long-term outcomes for patients with esthesioneuroblastoma. Head Neck. 2014;36(4):524–30.CrossRefPubMedGoogle Scholar
  56. 56.
    Venkatramani R, Pan H, Furman WL, et al. Multimodality treatment of pediatric esthesioneuroblastoma. Pediatr Blood Cancer. 2016;63(3):465–70.CrossRefPubMedGoogle Scholar
  57. 57.
    Su SY, Bell D, Ferrarotto R, et al. Outcomes for olfactory neuroblastoma treated with induction chemotherapy. Head Neck. 2017;39(8):1671–9.CrossRefPubMedGoogle Scholar
  58. 58.
    Franchi A, Rocchetta D, Palomba A, Degli Innocenti DR, Castiglione F, Spinelli G. Primary combined neuroendocrine and squamous cell carcinoma of the maxillary sinus: report of a case with immunohistochemical and molecular characterization. Head Neck Pathol. 2015;9(1):107–13.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of PathologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations